The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo-controlled, Phase III study in patients with myelofibrosis.
about
Janus kinase-1 and Janus kinase-2 inhibitors for treating myelofibrosisCritical appraisal of the role of ruxolitinib in myeloproliferative neoplasm-associated myelofibrosisJakpot! New small molecules in autoimmune and inflammatory diseasesHow ruxolitinib modified the outcome in myelofibrosis: focus on overall survival, allele burden reduction and fibrosis changes.Ruxolitinib for myelofibrosis--an update of its clinical effects.Ruxolitinib: long-term management of patients with myelofibrosis and future directions in the treatment of myeloproliferative neoplasmsRuxolitinib: a review of its use in patients with myelofibrosis.Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial.A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis.Low-dose ruxolitinib for improving leukopaenia and reducing recurrent infections associated with myelofibrosis.Efficacy and safety of ruxolitinib in the treatment of patients with myelofibrosis.JAK2 mutants (e.g., JAK2V617F) and their importance as drug targets in myeloproliferative neoplasmsMolecular determinants of pathogenesis and clinical phenotype in myeloproliferative neoplasms.The new landscape of therapy for myelofibrosis.Structural genomic alterations in primary mediastinal large B-cell lymphoma.Reducing symptom burden in patients with myeloproliferative neoplasms in the era of Janus kinase inhibitors.Myelofibrosis-When Do We Select Transplantation or Non-transplantation Therapeutic Options?JAK2 inhibitors for myeloproliferative neoplasms: what is next?Investigational Janus kinase inhibitors in development for myelofibrosis.Prognosis of Primary Myelofibrosis in the Genomic EraMyelofibrosis: an update on drug therapy in 2016.Epidemiology and clinical relevance of mutations in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 359 patients of the AGIMM group.Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis.SOHO State-of-the-Art Update and Next Questions: MPN.Targeting the IL-6/JAK/STAT3 signalling axis in cancer.Regulation of Malignant Hematopoiesis by Bone Marrow Microenvironment.Treatment With JAK Inhibitors in Myelofibrosis Patients Nullifies the Prognostic Impact of Unfavorable Cytogenetics.
P2860
Q24186554-427A4CDE-14BB-454D-967A-BDC2A0B34941Q26996258-DBA9697E-3243-4E42-9FAF-49D76B39E668Q27001957-ABB7B12F-4FC2-4D9D-B179-BA2A65CFA81FQ30240043-22545A20-F6FB-4741-8012-3407235FC5D2Q33411502-6601AA07-38AF-45AB-95C1-091800B38096Q33417217-EBABDF1F-8E0D-44B1-9ABB-44C8E8D385D2Q33419865-4A715747-3300-4A17-B115-CDD2C61F266BQ33439559-78A99351-5582-4A45-834C-7013AB2DEF3EQ36708975-B8B58597-E4CE-40F3-9765-2B89FFB93AD2Q36894603-52105536-AD50-4024-9764-E14BAFB26A2CQ37035925-6A3B2936-8D69-431B-BB5D-34C7CA8D0905Q37168138-2585A746-FF1A-4E42-AE85-D4867C1061D8Q37555785-201DB4E4-FD0E-48C7-96BA-6FB17AB83E3DQ38150261-90249153-1CCD-4DB1-B10F-C919980C261BQ38267888-FB5AA315-1254-4864-A836-8DD331278036Q38341625-0FB7C5CC-7621-4089-A9BE-C628D710F9F3Q38667263-C3D109B7-EB45-4053-AA0E-93FAFA8A1724Q38684435-E08A6D7F-DF55-4D8A-8522-DFDE19FFFE27Q38691019-784A87D1-7C02-4A4D-A526-35E2570B7766Q38926804-7381B47A-B5A2-4A7B-91CD-A77C6B4DB246Q38989215-E33CD3BF-C251-497E-A9FB-25AFFE900085Q39869997-86B4AC1E-8CD4-48EE-B0FA-CAFA3DAC2DEBQ40742224-DE2C7BDE-0B18-41B5-AF17-8FB5FE797D31Q49580473-5A07D2EC-99C3-4B25-8AA4-A1EA8248159CQ50191433-16B3C05F-34B6-45FC-8A5E-C3CDBD47AD33Q54968394-667C0A06-5973-47DA-89ED-2615B38200B1Q54981699-E8E1961C-65F6-49F6-8E5A-91E190288261
P2860
The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo-controlled, Phase III study in patients with myelofibrosis.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
The clinical benefit of ruxoli ...... n patients with myelofibrosis.
@en
type
label
The clinical benefit of ruxoli ...... n patients with myelofibrosis.
@en
prefLabel
The clinical benefit of ruxoli ...... n patients with myelofibrosis.
@en
P2093
P2860
P356
P1476
The clinical benefit of ruxoli ...... n patients with myelofibrosis.
@en
P2093
Carole Miller
Elizabeth Hexner
Elliott F Winton
Jason Gotlib
Jimmie H Harvey
John F DiPersio
John V Catalano
Kris Vaddi
Michael Deininger
P2860
P304
P356
10.1111/BJH.12274
P407
P577
2013-03-11T00:00:00Z